

EQA round: AP1/25 - Antithrombotic Agents

Deadline: 28.3.2025

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability						N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL				
Set 1															
(108) Apixaban	[µg/L]				59								59	54	92
Sample A1		286	19	6,5	59		CVP	286	5,9	25%	214	358	59	56	95
(38) Werfen (IL)		296	14	4,8	15	0							15		
(94) Stago		285	21	7,3	8	0							8		
(149) Siemens (Dade, BN, Dimension)		285	16	5,6	25	0							25		
(179) Siemens		276	13	4,6	7	0							7		
Other					4	0							4		
								3x 193, 1x 998							
Sample B1		65,8	7,1	11	59		CVP	65,8	2,3	25%	49,3	82,3	59	56	95
(38) Werfen (IL)		72,9	6,1	8,4	15	0							15		
(94) Stago		62,2	10	16	8	0							8		
(149) Siemens (Dade, BN, Dimension)		64,3	4,3	6,8	25	0							25		
(179) Siemens		64	3	4,6	7	0							7		
Other					4	0							4		
								3x 193, 1x 998							
Set 2															
(109) Dabigatran	[µg/L]				39								39	34	87
Sample A2		198	28	14	39		CVP	198	11	30%	138	258	39	35	90
(38) Werfen (IL)		171	10	6,1	10	0							10		
(149) Siemens (Dade, BN, Dimension)		194	7,8	4	11	0							11		
(179) Siemens		193	14	7,3	7	0							7		
(193) HYPHEN BioMed		231	15	6,5	9	0							9		
Other					2	0							2		
								2x 998							
Sample B2		54,9	6,5	12	39		CVP	54,9	2,6	30%	38,4	71,4	39	36	92
(38) Werfen (IL)		49,9	3,1	6,2	10	0							10		
(149) Siemens (Dade, BN, Dimension)		57,4	4,2	7,4	11	0							11		
(179) Siemens		52,5	5,2	9,9	7	0							7		
(193) HYPHEN BioMed		60,5	16	26	9	0							9		
Other					2	0							2		
								2x 998							
Set 3															
(110) Rivaroxaban	[µg/L]				61								61	57	93
Sample A3		319	22	6,9	61		CVP	319	6,9	25%	239	399	61	58	95
(38) Werfen (IL)		316	13	4,1	16	0							16		
(94) Stago		335	18	5,3	7	0							7		
(149) Siemens (Dade, BN, Dimension)		314	19	5,9	25	0							25		
(179) Siemens		323	40	12	7	0							7		
Other					6	0							6		
								4x 193, 2x 998							
Sample B3		81,8	6,5	7,9	61		CVP	81,8	2	25%	61,3	103	61	60	98
(38) Werfen (IL)		87,9	7,4	8,4	16	0							16		
(94) Stago		77,5	9,6	12	7	0							7		
(149) Siemens (Dade, BN, Dimension)		80	3,8	4,7	25	0							25		
(179) Siemens		82	7,4	9	7	0							7		
Other					6	0							6		
								4x 193, 2x 998							